Sales growth in generics drops
The growth in the global sales of generics has dived to 3.6% in 12 months – down from 11.4% in 2007, a new report says.
Read MoreAuthor: Katrina Megget
Germany gives Abstral thumbs up
ProStrakan and Orexo have announced their cancer pain drug Abstral has been approved in Germany.
Read MoreDiabetes drugs Avandia and Actos double risk of fractures in women
Questions are being asked about GlaxoSmithKline’s and Takeda’s Type 2 diabetes drugs after a study found the medicines were linked to higher bone fracture rates in women.
Read MoreGSK’s Avandia fails in atherosclerotic plaque study
GlaxoSmithKline’s diabetes drug Avandia (rosiglitazone) has failed to show it can significantly reduce atherosclerosis in patients with type 2 diabetes.
Read MoreChemotherapy causes death in more than 25% of cancer patients
A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases.
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
